Literature DB >> 19576363

Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin.

E Marc Jolicoeur1, E Magnus Ohman, Emily Honeycutt, Richard C Becker, Eric M Crespo, Gustavo B F Oliveira, David J Moliterno, Kevin J Anstrom, Christopher B Granger.   

Abstract

In a population of patients experiencing thrombocytopenia while treated with heparin, bleeding and thromboses are well-appreciated complications, but their relative contributions to mortality have been less well described. In this population, the aims of this study were (1) to identify the independent predictors of bleeding and (2) to compare the incidence and the strength of association of bleeding and of new thromboses to in-hospital mortality. The independent predictors of bleeding and in-hospital mortality were identified using multivariate logistic regression models on the 1,478 patients who developed thrombocytopenia after their enrollment in the Complications After Thrombocytopenia Caused by Heparin (CATCH) study. The independent predictors of bleeding were chronic hematologic disorders, intra-aortic balloon pump, congestive heart failure, and platelet count nadir <120 x 10(9)/L. Although bleeding (n = 141 [10%]) and thromboembolic complications (n = 135 [9%]) were equally prevalent, the former was less strongly associated than the latter with in-hospital mortality (odds ratio 1.75, 95% confidence interval 1.01 to 3.03, and odds ratio 2.77, 95% confidence interval 1.67 to 4.61, respectively). In conclusion, medical management should be directed mainly at the prevention of thromboembolic complications, while additionally considering the risk for bleeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576363     DOI: 10.1016/j.amjcard.2009.03.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.

Authors:  Renato D Lopes; David Garcia; Richard C Becker; Christopher B Granger; L Kristin Newby; John H Alexander; E Marc Jolicoeur; Allison Handler; Karen S Pieper; Antonio C Carvalho; Helio P Guimaraes; Dalton A F Chamone; Antonio C Baruzzi; Fabio S Machado; Ari Timerman; Antonio C Lopes
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

2.  Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021.

Authors:  José A G Agúndez; Elena García-Martín
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.